Compound selection for development - is salt formation the ultimate answer? Experiences with an extended concept of the "100mg approach".

In order to select the best candidates for development, physicochemical criteria such as solubility, chemical and physical stability, hygroscopicity, and thermal characteristics need to be evaluated as early as possible and balanced against other important criteria such as pharmacology or pharmacokinetics. It could be shown, that our miniaturized pharmaceutical profiling concept ("100mg approach"), is capable to reliably identify potential development issues of drug candidates, which, therefore, can be approached early on. Salt formation is a well established strategy to improve unfavorable properties, in particular poor solubility. This article describes our stepwise approach on salt screening, including selection criteria, and summarizes the observations we had during compound investigation. Considering a data base of 337 compounds (salts and uncharged substances), experiences with various counterions evaluated over the last 10years are discussed. We realized that salt formation usually improves poor solubility of a given candidate, but this is often at the cost of other attributes being relevant for pharmaceutical development. Surprisingly, in more than 50% of all cases the "free form" was finally selected after carefully weighing all compound characteristics. Therefore, we conclude that an early salt selection strategy is of utmost importance to predict potential development issues and to enable the provision of alternative physical forms. However, salt formation itself is not necessarily the best solution to meet all development requirements. The selection of a free form (acid or base) in combination with advanced formulation strategies should always be considered, sometimes as best compromise.

[1]  S. Balbach,et al.  Pharmaceutical evaluation of early development candidates "the 100 mg-approach". , 2004, International journal of pharmaceutics.

[2]  J C Bradford,et al.  Nephrotoxicity of pravadoline maleate (WIN 48098-6) in dogs: evidence of maleic acid-induced acute tubular necrosis. , 1993, Fundamental and applied toxicology : official journal of the Society of Toxicology.

[3]  R. Strickley,et al.  Preformulation Salt Selection. Physical Property Comparisons of the Tris(hydroxymethyl)aminomethane (THAM) Salts of Four Analgesic/Antiinflammatory Agents with the Sodium Salts and the Free Acids , 1987, Pharmaceutical Research.

[4]  F. Lombardo,et al.  Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. , 2001, Advanced drug delivery reviews.

[5]  Richard J. Bastin,et al.  Salt Selection and Optimisation Procedures for Pharmaceutical New Chemical Entities , 2000 .

[6]  Jochen Maas,et al.  An integrated early formulation strategy--from hit evaluation to preclinical candidate profiling. , 2007, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[7]  Donald C. Monkhouse,et al.  Review ArticlePharmaceutical Salts , 1977 .

[8]  William Jones,et al.  Occurrence of pharmaceutically acceptable anions and cations in the Cambridge Structural Database. , 2005, Journal of pharmaceutical sciences.

[9]  Karen C. Thompson,et al.  Discovery of a stable molecular complex of an API with HCl: a long journey to a conventional salt. , 2008, Journal of pharmaceutical sciences.

[10]  C. Lipinski Drug-like properties and the causes of poor solubility and poor permeability. , 2000, Journal of pharmacological and toxicological methods.

[11]  M. Bowker,et al.  Preparation of Water-Soluble Compounds Through Salt Formation , 2008 .

[12]  S. Venkatesh,et al.  Role of the development scientist in compound lead selection and optimization. , 2000, Journal of pharmaceutical sciences.

[13]  Jennifer B Dressman,et al.  Trends in active pharmaceutical ingredient salt selection based on analysis of the Orange Book database. , 2007, Journal of medicinal chemistry.

[14]  Filippos Kesisoglou,et al.  Nanosizing--oral formulation development and biopharmaceutical evaluation. , 2007, Advanced drug delivery reviews.

[15]  P. L. Gould,et al.  Salt selection for basic drugs , 1986 .

[16]  Xue-Qing Chen,et al.  Discovery pharmaceutics—Challenges and opportunities , 2006, The AAPS Journal.

[17]  Colin W Pouton,et al.  Formulation of poorly water-soluble drugs for oral administration: physicochemical and physiological issues and the lipid formulation classification system. , 2006, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[18]  G. Stephenson,et al.  Physical stability of salts of weak bases in the solid-state. , 2011, Journal of pharmaceutical sciences.

[19]  M. Peterson,et al.  Salt Screening and Selection , 2010, Burger's Medicinal Chemistry and Drug Discovery.

[20]  Elaine Merisko-Liversidge,et al.  Nanosizing: a formulation approach for poorly-water-soluble compounds. , 2003, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[21]  Christopher T. Walsh,et al.  Drugs as materials: valuing physical form in drug discovery , 2004, Nature Reviews Drug Discovery.

[22]  M. S. Ku,et al.  A biopharmaceutical classification-based Right-First-Time formulation approach to reduce human pharmacokinetic variability and project cycle time from First-In-Human to clinical Proof-Of-Concept , 2012, Pharmaceutical development and technology.

[23]  W. Tong,et al.  In situ salt screening--a useful technique for discovery support and preformulation studies. , 1998, Pharmaceutical development and technology.

[24]  V. Saxena,et al.  Developability assessment in pharmaceutical industry: An integrated group approach for selecting developable candidates. , 2009, Journal of pharmaceutical sciences.

[25]  D. Hauss Oral lipid-based formulations. , 2007, Advanced drug delivery reviews.

[26]  W. Tong,et al.  Impact of solid state properties on developability assessment of drug candidates. , 2004, Advanced drug delivery reviews.